MTOR and breast cancer: For instance, a decrease in PI3K/AKT/mTOR system activity by CTDs blocks the activation of crucial oncogenic molecules, i.e., MYC, which are inhibited in almost 50% of human cancers, including head and neck cancer, small-cell lung cancer, neuroblastoma, and breast cancer [88,93].